Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. (HOOK) has described itself as a clinical-stage biopharmaceutical company developing next generation immunotherapeutics based on a proprietary arenavirus platform. Its news flow has highlighted programs in oncology and serious infectious diseases, including product candidates targeting HPV16-positive cancers, KRAS mutated cancers, and viral infections such as hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
Company press releases provide detailed updates on its collaboration and license agreement with Gilead Sciences, Inc. For example, HOOKIPA has reported on the HB-400 program in clinical development for HBV and the HB-500 program, a next-generation therapeutic vaccine being evaluated as a potential component of a curative regimen for HIV. News items have described clinical milestones such as enrollment completion in a Phase 1b trial of HB-500, including trial design elements and the intended role of HB-500 in a combination strategy for a potential functional cure of HIV.
HOOKIPA’s news coverage has also included significant corporate and strategic developments. In early 2025, the company issued multiple announcements related to a potential all-share combination with Poolbeg Pharma plc and associated U.K. Takeover Code disclosure requirements, followed by a Rule 2.8 statement that it did not intend to make an offer under Rule 2.7 of the Code. Subsequent releases detailed an asset purchase agreement with Gilead for HOOKIPA’s HB-400 program assets and certain HB-500 assets, and explained how this transaction related to the company’s long-term prospects and strategies.
Later announcements document HOOKIPA’s intention to voluntarily delist its common stock from the Nasdaq Capital Market, deregister its common stock under the Securities Exchange Act of 1934, and seek stockholder approval for dissolution and liquidation. Investors using this news page can review the sequence of clinical updates, collaboration news, U.K. takeover-related disclosures, and corporate actions such as the asset sale to Gilead, the special meeting of stockholders, and the steps toward delisting and deregistration. This provides a consolidated view of both scientific progress and material corporate events affecting HOOKIPA and the HOOK symbol.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.